Agios Pharma (AGIO) Reports Q4 Loss of $1.08/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Leerink Partners Remains Sidelined on Agios Pharma (AGIO) - PT to $56
February 19, 2016 7:30 AM ESTLeerink Partners maintained a Market Perform rating on Agios Pharma (NASDAQ: AGIO), and cut the price target to $56.00 (from $62.00), following the company's 4Q earnings call. AGIO provided a number of incremental pipeline updates. Leerink sees the announced AG-348 and AG-519 data at EHA in June and... More
